Manoush Masarrat new CEO for Inhalation Sciences AB (publ)
STOCKHOLM, SWEDEN – 13 September, 2019. Inhalation Sciences, which develops and commercializes world-leading instruments for inhalation research, today announces that Manoush Masarrat will be appointed new CEO. Manoush is currently a member of the company's Board of Directors. He has extensive knowledge of the company's products and strategy. Manoush's first day as CEO will be September 16 2019.
Inhalation Sciences (ISAB) previously announced that Lena Heffler requested her resignation as CEO on her own initiative, choosing to leave for personal reasons. Manoush Masarrat will take up the post of ISAB CEO on September 16. He will also leave his post as a member of the company's Board of Directors. Lena Heffler will remain in the Company's organization during the notice period of six months, focusing on her core areas of expertise; marketing, sales and project management.
Manoush Masarrat has been a member of the Company's Board of Directors since December 2018. He was elected to the board because of his extensive experience of the commercialization of medtech products and companies. Manoush has most recently been CEO of Exscale Biospecimen Solutions, and has previously held leading positions in sales and marketing at companies including Medical vision, Electrocore and ArthroCare.
ISAB is currently facing an exciting period of development. The clinical validation of its flagship system PreciseInhale, together with continued growth of its customer base in the preclinical arena, will enable the company to enter into more and broader commercial partnerships.
Manoush Masarrat -”PreciseInhale is a clear leader in its niche, as proven by its strong customer base of many large and established companies. From that base I want to help ISAB up to the next level. For me that means broader commercial partnerships and agreements. Our technology being validated for clinical use opens up the opportunity for us to make a serious difference in the development of new inhalable drugs.”
The company's Chairman of the Board Fredrik Sjövall: “We are very pleased that Manoush has decided to step up as CEO of Inhalation Sciences. Manoush has exactly the right background, character and drive to continue developing PreciseInhale into a world-leading platform for the development of new inhaled drugs. That he been able and willing to take up the role at such short notice is superb. Manoush knows the company from a strategic perspective, and with Lena remaining with us in the company during the interim period we have excellent conditions to get the new role operational quickly and efficiently.”
For more information on Inhalation Sciences, please contact:
Fredrik Sjövall, Chairman of the Board
E-mail: fredrik.sjovall@inhalation.se
Mobile: +46 (0)70 64 508 75
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.
The information above was provided by Inhalation Sciences Sweden AB (publ) through the above contact person, for publication on September 13, 2019
Tags: